Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03131583 | The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout | PHASE1 | COMPLETED | 15 | — | — | Feb 17, 2017 | Jan 29, 2018 | Aug 8, 2019 | 1 | China |
PK profile
PK profile
PK profile
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Colchicine 0.5 mg Oral Tablet Day-14\~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3\~Day8 qd. |
| Name | Type | Description |
|---|---|---|
| Colchicine | DRUG | Day-14\~Day16 qd |
| Febuxostat | DRUG | Day1 and Day8 qd |
| SHR4640 | DRUG | Day3\~Day8 qd |
Inclusion Criteria: 1. Subject has a body mass index ≥18.5 and ≤30 kg/m2; 2. Screening sUA value ≥8mg/dl; 3. Subject has no clinically relevant abnormalities in vital signs, ECG, physical examination，imaging examination or safety laboratory values. Exclusion Criteria: 1. Subject known or suspecte...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| Protalix | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |